156P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib study
C. Cui(Peking University), Jun Guo(Hebei Medical University), Hongming Pan(Sir Run Run Shaw Hospital), Xinyu Li(BeiGene (China)), X. Wang(Peking University), Lu Yang(Wuhan University), Jiahang Sun(Harbin Medical University), Matteo S. Carlino(The University of Sydney), Jiuwei Cui(Jilin University)
Cited by 1
Related Papers
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656